Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway.

in Journal of virology by Makoto Fukuda, Richard Longnecker

TLDR

  • This study looked at how a protein called LMP2A affects the way cells respond to a signal from a molecule called TGF-beta 1. The study found that LMP2A activates a pathway called PI3-K/Akt, which helps cells survive. The study also found that LMP2A partially blocks the ability of TGF-beta 1 to cause cells to die. This study suggests that LMP2A could be a potential target for cancer treatment by blocking the PI3-K/Akt pathway.

Abstract

Latent membrane protein 2A (LMP2A) blocks B-cell receptor signal transduction in vitro by binding the Syk and Lyn protein tyrosine kinases. As well as blocking B-cell signal transduction, LMP2A has been shown to activate the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway, which acts as a survival signal in both B cells and epithelial cells. Transforming growth factor beta 1 (TGF-beta 1) is a multifunctional cytokine that plays important roles in regulating cell growth and differentiation in many biological systems. The loss of the growth-inhibitory response to the TGF-beta 1 signal is found in many cancers and is widely thought to promote tumor development. In this study, we found that LMP2A induced the phosphorylation of Akt (serine 473) in Burkitt's lymphoma cell line Ramos and in gastric carcinoma cell line HSC-39 and partially enhanced cell viability following TGF-beta 1 treatment. In addition, LMP2A partially inhibited TGF-beta 1-induced DNA fragmentation and cleavage of poly(ADP-ribose) polymerase (PARP). In the presence of LY294002, an inhibitor of PI3-K, the LMP2A-mediated inhibitory effects on TGF-beta 1-induced DNA fragmentation and cleavage of PARP were alleviated. Furthermore, LMP2A did not alter the levels of expression of type I and type II TGF-beta 1 receptors. Taken together, these results suggest that LMP2A may inhibit TGF-beta 1-mediated apoptosis through activation of the PI3-K/Akt pathway.

Overview

  • The study investigates the role of latent membrane protein 2A (LMP2A) in regulating B-cell receptor signal transduction and its impact on transforming growth factor beta 1 (TGF-beta 1)-induced apoptosis in Burkitt's lymphoma and gastric carcinoma cells. The hypothesis being tested is whether LMP2A activates the PI3-K/Akt pathway and inhibits TGF-beta 1-mediated apoptosis in these cells. The methodology used includes in vitro experiments with Ramos and HSC-39 cells, with LMP2A expression and TGF-beta 1 treatment as the experimental conditions. The primary objective of the study is to determine the role of LMP2A in regulating TGF-beta 1-induced apoptosis in B cells and epithelial cells through the PI3-K/Akt pathway.

Comparative Analysis & Findings

  • The study found that LMP2A induced the phosphorylation of Akt (serine 473) in both Ramos and HSC-39 cells and partially enhanced cell viability following TGF-beta 1 treatment. LMP2A also partially inhibited TGF-beta 1-induced DNA fragmentation and cleavage of poly(ADP-ribose) polymerase (PARP) in these cells. The results suggest that LMP2A may inhibit TGF-beta 1-mediated apoptosis through activation of the PI3-K/Akt pathway.

Implications and Future Directions

  • The study's findings have important implications for understanding the role of LMP2A in regulating TGF-beta 1-induced apoptosis in B cells and epithelial cells. The study identifies a potential therapeutic target for cancer treatment by targeting the PI3-K/Akt pathway. Future research could further explore the role of LMP2A in regulating TGF-beta 1-induced apoptosis and its potential as a therapeutic target in cancer.
Read Full Article